Preclinical evaluation of novel treatment strategies in patient-derived xenograft (PDX) models of pancreatic cancer
PDX Expert: Dr. Diana Behrens
Dr. Behrens provided information about the development of new models for pancreatic cancer and how to evaluate combination therapies in preclinical models.
The described PDX panel clearly reflects clinical pancreatic cancer histology, growth and inherent and acquired treatment resistance as well as recurrent disease.
Preclinal models of patient-derived xenografts on humanized mice for translational immuno-oncology research
Dr. Annika Wulf-Goldenberg
Dr. Wulf-Goldenberg is one of our most experienced experts in immune oncology research.
Learn more about our capability to engraft patient-derived tumor xenografts (PDX) on humanized mice and how to evaluate the combination of radiotherapy with immune checkpoint inhibition, in syngeneic cancer models.
. find out further 500 well characterized PDX models: www.epo-berlin.com
(search online for molecular and pharmacological characteristics)